Machina Capital S.A.S. Buys Shares of 5,202 Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Machina Capital S.A.S. bought a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the fourth quarter, HoldingsChannel.com reports. The fund bought 5,202 shares of the medical equipment provider’s stock, valued at approximately $633,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of ZBH. Private Advisor Group LLC raised its holdings in Zimmer Biomet by 12.3% during the fourth quarter. Private Advisor Group LLC now owns 10,610 shares of the medical equipment provider’s stock worth $1,291,000 after purchasing an additional 1,164 shares in the last quarter. SYM FINANCIAL Corp bought a new stake in Zimmer Biomet during the fourth quarter worth approximately $201,000. River Global Investors LLP raised its holdings in Zimmer Biomet by 13.9% during the fourth quarter. River Global Investors LLP now owns 16,479 shares of the medical equipment provider’s stock worth $2,006,000 after purchasing an additional 2,012 shares in the last quarter. Benjamin F. Edwards & Company Inc. raised its holdings in Zimmer Biomet by 186.0% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 1,885 shares of the medical equipment provider’s stock worth $229,000 after purchasing an additional 1,226 shares in the last quarter. Finally, Natixis Advisors L.P. raised its holdings in Zimmer Biomet by 4.3% during the fourth quarter. Natixis Advisors L.P. now owns 150,825 shares of the medical equipment provider’s stock worth $18,355,000 after purchasing an additional 6,204 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Trading Down 0.9 %

NYSE ZBH traded down $1.09 on Monday, hitting $120.57. 1,293,796 shares of the stock were exchanged, compared to its average volume of 1,480,384. The company’s 50-day moving average price is $125.17 and its two-hundred day moving average price is $120.32. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.66 and a quick ratio of 0.80. Zimmer Biomet Holdings, Inc. has a 52-week low of $102.00 and a 52-week high of $147.50. The company has a market capitalization of $24.80 billion, a price-to-earnings ratio of 26.10, a P/E/G ratio of 2.23 and a beta of 1.03.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.94 EPS for the quarter, beating the consensus estimate of $1.87 by $0.07. Zimmer Biomet had a net margin of 12.93% and a return on equity of 12.70%. The business had revenue of $1.89 billion for the quarter, compared to analysts’ expectations of $1.87 billion. During the same period in the previous year, the company posted $1.89 EPS. Zimmer Biomet’s revenue was up 3.2% on a year-over-year basis. Research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.1 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th were issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.80%. The ex-dividend date was Wednesday, March 27th. Zimmer Biomet’s dividend payout ratio is currently 20.78%.

Insider Activity

In related news, VP Chad F. Phipps sold 26,156 shares of Zimmer Biomet stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total value of $3,364,184.72. Following the completion of the sale, the vice president now owns 44,145 shares of the company’s stock, valued at approximately $5,677,929.90. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.70% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

ZBH has been the topic of several recent analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $140.00 price target on shares of Zimmer Biomet in a report on Friday, February 9th. Truist Financial dropped their price target on Zimmer Biomet from $137.00 to $130.00 and set a “hold” rating on the stock in a report on Friday. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a report on Thursday. Evercore ISI upped their price target on Zimmer Biomet from $125.00 to $130.00 and gave the company an “in-line” rating in a report on Thursday, April 4th. Finally, Oppenheimer upped their price target on Zimmer Biomet from $150.00 to $155.00 and gave the company an “outperform” rating in a report on Friday. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $135.40.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.